51 patents
Utility
Cassette encoding a FPV/brachyury fusion protein
12 Sep 23
The present invention relates to one or more promoters and/or expression cassettes that can be used for enhancing expression of a heterologous gene, such as Brachury.
Zengji Li, Alain Delcayre, Ryan Rountree
Filed: 28 Jul 16
Utility
Combination therapy for treating cancer with an antibody and intravenous administration of a recombinant MVA
15 Aug 23
The invention relates to a pharmaceutical combination and related methods for reducing tumor volume and/or increasing the survival of a cancer patient.
Hubertus Hochrein, Henning Lauterbach, José Medina Echeverz, Matthias Habjan
Filed: 14 Mar 22
Utility
Poxvirus vectors encoding HIV antigens, and methods of use thereof
15 Aug 23
Poxvirus vectors encoding a synthetic HIV envelope antigen and other HIV antigens, as well as compositions containing such poxvirus vectors and uses of such poxvirus vectors as vaccines to provide improved immunity against HIV, are provided.
Frank Wegmann, Johannes Petrus Maria Langedijk, Jerôme Hubertina Henricus Victor Custers, Viki Bockstal, Markus Kalla
Filed: 10 Dec 21
Utility
A Recombinant Modified Vaccinia Virus (MVA) Vaccine Against Coronavirus Disease
27 Jul 23
The invention relates to a recombinant Modified Vaccinia Virus Ankara (MVA) encoding a spike (S) protein or a part thereof, such as a receptor-binding domain (RBD), and additional antigenic sequences derived from other proteins of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of coronavirus disease 19 (COVID-19).
Jürgen Hausmann, Robin Steigerwald, Matthias Habjan, José Medina Echeverz, Stephan Rambichler
Filed: 10 Jun 21
Utility
Compositions and methods for enhancing the stability of transgenes in poxviruses
23 May 23
Provided herein are recombinant poxviruses that are stable through successive passaging of the recombinant poxviruses.
Markus Kalla, Ryan Rountree, Ulrike Dirmeier
Filed: 5 Jul 21
Utility
Conditions Improving Poxvirus Stability
13 Apr 23
The present invention relates to aqueous compositions conferring improved stability to poxvirus during storage as well as to the use of such compositions and methods for preparing the same.
Katrine Kjaer, Markus Kalla
Filed: 12 Mar 21
Utility
Medical Uses of 4-1BBL Adjuvanted Recombinant Modified Vaccinia Virus Ankara (MVA)
23 Feb 23
The invention relates to a recombinant Modified Vaccinia Virus Ankara (MVA) expressing a TAA and the costimulatory molecule 4-1BBL for use in (i) the prevention of recurrence of a solid tumor, wherein the recombinant MVA is intratumorally administered to the solid tumor, or (ii) the treatment, prevention and/or prevention of recurrence of a tumor, wherein the recombinant MVA is intratumorally administered to another solid tumor.
Maria Hinterberger, José Medina Echeverz, Mathias Habjan, Jügen Hausmann, Markus Kalla
Filed: 20 Nov 20
Utility
Recombinant modified vaccinia virus ankara (MVA) equine encephalitis virus vaccine
7 Feb 23
The present invention relates to recombinant modified vaccinia virus Ankara (MVA) and to methods of using the same.
Robin Steigerwald, Markus Kalla
Filed: 4 Jan 21
Utility
Combination Therapy for Treating Cancer With an Antibody and Intravenous Administration of a Recombinant MVA
11 Aug 22
The invention relates to a pharmaceutical combination and related methods for reducing tumor volume and/or increasing the survival of a cancer patient.
Hubertus HOCHREIN, Henning LAUTERBACH, José MEDINA ECHEVERZ, Matthias HABJAN
Filed: 14 Mar 22
Utility
Multivalent recombinant modified vaccinia virus ankara (MVA) vector encoding filovirus immunogens
24 May 22
The present invention relates to an improved filovirus vaccine comprising a recombinant modified vaccinia virus Ankara-based (MVA-based) vaccine against filovirus infection and to related products, methods and uses.
Ariane Volkmann, Robin Steigerwald, Hubertus Hochrein, Ulrike Dirmeier, Henning Lauterbach, Jürgen Hausmann
Filed: 27 Feb 20
Utility
Methods and Compositions for Inducing Protective Immunity Against Filovirus Infection
24 Mar 22
The present invention provides compositions, vaccines and methods for inducing protective immunity against filovirus infection, particularly protective immunity against infection of one or more subtypes of Ebola viruses and Marburg virus.
Ariane VOLKMANN, Robin STEIGERWALD, Ulrike DIRMEIER, Maria Grazia PAU, Benoit Christophe Stephan CALLENDRET, Lucy A. WARD
Filed: 11 Oct 21
Utility
Poxvirus Vectors Encoding HIV Antigens, and Methods of Use Thereof
24 Mar 22
Poxvirus vectors encoding a synthetic HIV envelope antigen and other HIV antigens, as well as compositions containing such poxvirus vectors and uses of such poxvirus vectors as vaccines to provide improved immunity against HIV, are provided.
Frank Wegmann, Johannes Petrus Maria Langedijk, Jerôme Hubertina Henricus Victor Custers, Viki Bockstal, Markus Kalla
Filed: 10 Dec 21
Utility
Combination therapy for treating cancer with an intravenous administration of a recombinant MVA and an antibody
15 Mar 22
The invention relates to a pharmaceutical combination and related methods for reducing tumor volume and/or increasing the survival of a cancer patient.
Hubertus Hochrein, Henning Lauterbach, José Medina Echeverz, Matthias Habjan
Filed: 23 Aug 18
Utility
Poxvirus vectors encoding HIV antigens, and methods of use thereof
25 Jan 22
Poxvirus vectors encoding a synthetic HIV envelope antigen and other HIV antigens, as well as compositions containing such poxvirus vectors and uses of such poxvirus vectors as vaccines to provide improved immunity against HIV, are provided.
Frank Wegmann, Johannes Petrus Maria Langedijk, Jerôme Hubertina Henricus Victor Custers, Viki Bockstal, Markus Kalla
Filed: 14 Jun 18
Utility
Stable recombinant MVA vectors comprising modified RSV genes with reduced intramolecular recombinatorial activity
18 Jan 22
The invention relates to vectors comprising two or more homologous nucleotide sequences and methods for generating them.
Robin Steigerwald
Filed: 7 Sep 18
Utility
Therapy for Treating Cancer with an Intratumoral or Intravenous Administration of a Recombinant MVA Encoding 4-1BBL (CD137L) and/or CD40L
6 Jan 22
The invention relates to a composition and related methods for reducing tumor volume and/or increasing the survival of a cancer patient.
Henning Lauterbach, Maria Hinterberger, José Medina Echeverz
Filed: 20 Nov 19
Utility
Recombinant Modified Vaccinia Virus Ankara (MVA) Foot and Mouth Disease Virus (FMDV) Vaccine
23 Dec 21
The present invention relates to modified poxviral vectors and to methods of making and using the same.
Robin Steigerwald, Markus Kalla
Filed: 30 Aug 21
Utility
Methods and compositions for inducing protective immunity against filovirus infection
16 Nov 21
The present invention provides compositions, vaccines and methods for inducing protective immunity against filovirus infection, particularly protective immunity against infection of one or more subtypes of Ebola viruses and Marburg virus.
Ariane Volkmann, Robin Steigerwald, Ulrike Dirmeier, Maria Grazia Pau, Benoit Christophe Stephan Callendret, Lucy A. Ward
Filed: 17 Oct 19
Utility
MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen
16 Nov 21
Compositions and methods are described for generating an improved effective immune response against an immunogen in humans.
Benoit Christophe Stephan Callendret, Kerstin Luhn-Wegmann
Filed: 6 Apr 18
Utility
Compositions and Methods for Enhancing the Stability of Transgenes in Poxviruses
4 Nov 21
Provided herein are recombinant poxviruses that are stable through successive passaging of the recombinant poxviruses.
Markus Kalla, Ryan Rountree, Ulrike Dirmeier
Filed: 5 Jul 21